1
Gene therapy has entered a complicated phase. Over the past several years, the field has delivered remarkable scientific breakthroughs alongside sobering challenges—clinical safety concerns, manufacturing bottlenecks, and treatments priced in the millions of dollars. Some biotechnology companies have scaled back programs, while investors have grown cautious about the pace of commercial progress.
Despite these growing pains, gene therapy remains one of the most promising strategies for treating genetic diseases. Beneath the…